Business Insider

Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis

ATLANTA, June 20, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the ...
Business Insider

Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

ATLANTA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the ...
KRON4 News

Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners ...
Nasdaq

Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®

ATLANTA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today the ...
Healio

VIDEO: Fluocinolone acetonide implant shows promise for treatment of noninfectious uveitis

Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Danny A. Mammo, MD, presents data ...
Business Wire

Clearside Biomedical, Inc. Reports Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced ...
PR Newswire

YUTIQ Sees Continued Market Growth in Treatment of Chronic Non-Infectious Uveitis | DelveInsight

YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The uveitis treatment market is projected to grow steadily, ...
Becker's ASC

FDA approves EyePoint Pharmaceuticals’ Yutiq — 5 notes

The FDA approved Yutiq, a fluocinolone acetonide intravitreal implant for treating chronic non-infectious uveitis affecting the eye’s posterior segment. 1. EyePoint Pharmaceuticals’ Yutiq is a ...
Hosted on MSN

Injectable obesity medications associated with reduced risk for eye inflammation

Cleveland Clinic Cole Eye Institute researchers have identified a potential association between the use of GLP-1 receptor agonist (GLP-1RA) therapy and a reduced risk of non-infectious uveitis, a type ...
Seeking Alpha

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis

VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA ...
Nasdaq

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non ...

Encinitas, California--(Newsfile Corp. - August 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has been granted U.S. (Patent # 11,730,716) and ...